How about tonghua dongbao stock?

1 is a good stock, and many brokers are optimistic. In history, you can make money by buying any amount of money. As long as the meat is not cut, the stock will not lose money. Most of its main business is related to the production of medical drugs, so it should be the pharmaceutical industry, with good growth in the medium and long term. It is estimated that the company's net profit will increase by 1 10% and 80% respectively in 2008 and 2009, and the actual earnings per share will be 0.40 yuan and 0.72 yuan respectively. Large overseas orders are not considered in the forecast. It is expected that the installation and commissioning will be completed in March 2008 and the trial production will begin. The company's insulin raw materials and preparations have been licensed to export insulin to Southeast Asian countries and some eastern European countries, and any large order will be a catalyst for the stock price increase.

2. Dongbao inflection point appears with good growth. Can be held for a long time. Close today 13.45. You can see 20 yuan this year, don't worry. Tonghua dongbao was co-founded by Dongbao Industrial Group Co., Ltd., Tonghua Petroleum Tool Factory and Tonghua Changbai Mountain Pharmaceutical Factory in 1992. Its predecessor was Tonghua Changbai Mountain No.5 Pharmaceutical Factory, which was established in February 1985. 1In July, 1994, the company issued A shares and listed them on the Shanghai Stock Exchange. The company is a private enterprise, and the actual controller is Mr. Li Yikui.

In the mid-1980s, tonghua dongbao successfully trial-produced the first trump card product-fresh ginseng royal jelly, which accumulated certain capital for the company. Subsequently, the company developed Zhennaoning capsule, which has been selling well for more than ten years; In the 1990s, the company invested hundreds of millions of yuan in the research and development of recombinant human insulin, and successfully developed the first recombinant human insulin with independent intellectual property rights in China from June 05438 to June 0998. At present, the company's business mainly includes building materials, plastic steel doors and windows, and medicine. Medicine is an important source of income, accounting for 73% of the company's total revenue, while building materials revenue only accounts for 27%. Moreover, because the gross profit margin of medicine is as high as 58%, far exceeding the gross profit margin of building materials by 25%, the contribution rate of medicine business has increased to 86.6%, and the profit contribution rate of building materials business has decreased to 65,438+03.4%. Tonghua dongbao's insulin exports to overseas markets: mainly to start and meet the potential demand of diabetes, rather than to seize the market share of the two multinational giants. Taking China, the largest developing country, as an example, the incidence of diabetes and the market demand for insulin are increasing at an annual rate of 30%, and the sales of insulin in 2008 are close to 3 billion yuan.